CAFI CONSUMER AUTOMOTIVE FIN INC

Consumer Automotive Finance, Inc. Announces Nationwide Teleconference as It Transitions to Fifty 1 Labs, Inc.

Consumer Automotive Finance, Inc. Announces Nationwide Teleconference as It Transitions to Fifty 1 Labs, Inc.

MELBOURNE, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- via IBN – Consumer Automotive Finance, Inc. (), soon to be rebranded as Fifty 1 Labs, Inc., a dynamic leader in the sports supplement, fitness equipment, and health and wellness sectors, is proud to announce a nationwide teleconference to be hosted on the XSpaces platform on March 12, 2025.

The teleconference will feature retired NFL star and company President Brandon Spikes, who will address shareholder questions and discuss the exciting roadmap for 2025 and beyond. This interactive session is designed to offer current and prospective shareholders an exclusive look into the strategic initiatives, innovative product developments, and forward-thinking vision that will shape the future of Fifty 1 Labs.

The Company recently announced the finalization of an agreement to retire 246 million of its issued and outstanding common shares. This transformative action, executed with precision by the company's management team, underscores an unwavering dedication to fortifying shareholder value and optimizing its capital structure as it continues to thrive on the OTC market.

"I am thrilled to engage directly with our valued shareholders as we unveil our plans for the coming year. Our commitment to innovation in sports supplements, fitness equipment, and overall health and wellness is stronger than ever, and I look forward to discussing how our evolving strategy will drive growth and success," said Brandon Spikes, President of Fifty 1 Labs.

Key highlights of the teleconference include:

  • Shareholder Q&A Session: An open forum for shareholders to get answers to questions and gain insights directly from leadership.
  • 2025 Roadmap Overview: Detailed discussion of upcoming strategic initiatives and growth opportunities.
  • Interactive Engagement: Participation via the XSpaces platform, offering a seamless experience for all attendees.

Fifty 1 Labs, Inc. invites all shareholders—both current and future—to join this important event. Shareholders are encouraged to send in questions in advance to participate in the discussion.

For more information about the teleconference and registration details, please visit [company website] or contact:

Media Contact:

Fifty 1 Labs, Inc.

Email:

For more information, please visit .

About Fifty 1 Labs, Inc.

Consumer Automotive Finance, Inc. (OTCPK: CAFI), soon to be renamed Fifty 1 Labs, Inc., is a publicly traded company focused on sports supplementation, fitness equipment, and holistic wellness. The company operates four key subsidiaries: 51, LLC, which specializes in sports supplements; The Quickness, which offers patented athletic training equipment; Astound NMN, a leader in anti-aging and DNA repair supplements; and Drago Knives, patented knife throwing technology. Fifty 1 Labs, Inc. is also actively pursuing strategic acquisitions to expand its portfolio and drive sustainable growth.

Safe Harbor Statement:

The information provided in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Identifiable by words such as "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions, these statements may also be made in written or oral form in the company's filings with the U.S. Securities and Exchange Commission, OTC Markets, press releases, other written materials, or in oral statements made by its officers, directors, or employees to third parties. There can be no assurance that such statements will prove to be accurate. The company cautions that these forward-looking statements are further qualified by other factors including, but not limited to, those set forth in the company's Disclosure Statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, and various other factors beyond the company's control. The company does not undertake any obligation to update publicly or to revise any statements in this release, whether as a result of new information, future events, or otherwise.

Investor Relations Contact:

Investor Relations

877-814-4188

Wire Service Contact:

IBN

Austin, Texas



512.354.7000 Office



EN
27/02/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONSUMER AUTOMOTIVE FIN INC

 PRESS RELEASE

Fifty 1 Labs Inc. Appoints Dr. Joel Gagnier as Chief Science Officer

Fifty 1 Labs Inc. Appoints Dr. Joel Gagnier as Chief Science Officer Pioneering Evidence-Based AI Innovation in Personalized Wellness and Health Research VANCOUVER, British Columbia, Oct. 09, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: ) and a cutting-edge innovator at the intersection of AI, clinical research, and personalized wellness, today announced the appointment of Dr. Joel Gagnier, BA, ND, MSc, PhD, as Chief Science Officer (CSO). This strategic leadership addition underscores Fifty1 AI Labs' commitment to rigorous scientific stand...

 PRESS RELEASE

Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Techno...

Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc. Strategic Acquisition Bolsters AI-Driven Healthcare Innovation, Positioning Fifty 1 Labs as a Leader in Clinical Data Analytics VANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 Labs Inc. (OTC: ), a leader in AI-powered healthcare and biotechnology solutions, is excited to announce the signing of a Letter of Intent (LOI) to acquire BioSpark AI Technologies Inc., a Vancouver-based innovator specializing in patented artificial intelligence systems for clinical data extraction...

 PRESS RELEASE

Fifty 1 Labs, Inc. Engages PCAOB Auditing Firm to Prepare for Uplist t...

Fifty 1 Labs, Inc. Engages PCAOB Auditing Firm to Prepare for Uplist to OTCQB Fifty 1 Labs continues to advance its portfolio of biotech and wellness initiatives VANCOUVER, British Columbia, Sept. 23, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 Labs, Inc, () a Nevada-based holding company revolutionizing health, wellness, and biotech through AI-driven drug repurposing and functional medicine, today announced that it has signed a letter of engagement with a Public Company Accounting Oversight Board (PCAOB) registered auditing firm. The engagement covers audits of the Company's 2024 and 2...

 PRESS RELEASE

Fifty1 Labs, Inc. Leadership Publishes Landmark Framework to Unlock Gl...

Fifty1 Labs, Inc. Leadership Publishes Landmark Framework to Unlock Global Oncology Data Through AI-Driven Real-World Evidence Leadership Team's Technical Primer Enhances Real-World Evidence (RWE) for Cross-Border Impact, Positioning Fifty1 AI Labs in a $48B Market Opportunity VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- via IBN – Fifty1 AI Labs, a subsidiary of Fifty1 Labs, Inc. (OTC: ), announces the publication of a landmark technical primer on "transportability" methods in oncology real-world evidence (RWE). Authored by CTO Alind Gupta and CEO Paul Arora, the prim...

 PRESS RELEASE

Fifty1 Labs Partners with LUNR Aerospace to Pioneer AI-Driven Drug Rep...

Fifty1 Labs Partners with LUNR Aerospace to Pioneer AI-Driven Drug Repurposing for Space Medicine, Strategic Collaboration Aims to Harness AI and Orbital Access to Revolutionize Astronaut Health Solutions in a $2 Billion Market by 2032 VANCOUVER, British Columbia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- via IBN --  Fifty 1 AI Labs, a subsidiary of Fifty 1 Labs, Inc. (), has entered a groundbreaking partnership with LUNR Aerospace to develop AI-driven drug repurposing initiatives tailored for space medicine. This collaboration targets critical health challenges in microgravity, including immune ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch